Corcept Therapeutics (CORT) EBT (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of EBT data on file, last reported at -$44.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 564.91% year-over-year to -$44.7 million; the trailing twelve-month figure through Mar 2026 stood at $12.1 million (down 91.09% YoY), and the FY2025 full-year result was $66.5 million, down 58.84% from the prior year.
• EBT eased to -$44.7 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $52.9 million in Q3 2024 to a low of -$44.7 million in Q1 2026.
• A 5-year average of $24.9 million and a median of $32.0 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT jumped 89.83% in 2024 and tumbled 564.91% in 2026, its largest moves.
• Tracing CORT's EBT over 5 years: stood at $24.3 million in 2022, then surged by 51.63% to $36.8 million in 2023, then dropped by 13.17% to $32.0 million in 2024, then plunged by 68.99% to $9.9 million in 2025, then sank by 551.21% to -$44.7 million in 2026.
• Business Quant data shows CORT's EBT at -$44.7 million in Q1 2026, $9.9 million in Q4 2025, and $15.2 million in Q3 2025.